Extensive research has been conducted on post-mortem brain tissue in schizophrenia (SCZ), particularly the dorsolateral prefrontal cortex (DLPFC). However, to what extent the reported changes are due to the disorder itself, and which are the cumulative effects of lifetime medication remains to be determined. In this study, we employed label-free liquid chromatography-mass spectrometry-based proteomic and proton nuclear magnetic resonance-based metabonomic profiling approaches to investigate DLPFC tissue from two cohorts of SCZ patients grouped according to their lifetime antipsychotic dose, together with tissue from bipolar disorder (BPD) subjects, and normal controls (n = 10 per group). Both techniques showed profound changes in tissue from low-cumulative-medication SCZ subjects, but few changes in tissue from medium-cumulative-medication subjects. Protein expression changes were validated by Western blot and investigated further in a third group of subjects who were subjected to high-cumulative-medication over the course of their lifetime. Furthermore, key protein expression and metabolite level changes correlated significantly with lifetime antipsychotic dose. This suggests that the detected changes are present before antipsychotic therapy and, moreover, may be normalized with treatment. Overall, our analyses revealed novel protein and metabolite changes in low-cumulative-medication subjects associated with synaptogenesis, neuritic dynamics, presynaptic vesicle cycling, amino acid and glutamine metabolism, and energy buffering systems. Most of these markers were altered specifically in SCZ as determined by analysis of the same brain region from BPD patients.
Introduction
Schizophrenia (SCZ) is a debilitating psychiatric disorder that affects B1% of the world population. 1 Extensive research has been conducted to investigate brain regions such as the dorsolateral prefrontal cortex (DLPFC) as this area is thought to represent the primary site of higher cognitive function impairment. 2 For example, cytoarchitectural, neurochemical 3 and structural 4 abnormalities have been observed in this brain region of SCZ patients, such as decreased neuronal size and dendritic spine density. [5] [6] [7] [8] Evidence in favour of abnormal neurotransmission, signal transduction, 9 neural connectivity, GABAergic 10 and glutamatergic activity 11 has also been demonstrated in the DLPFC of these patients. There has been increasing interest in employing global protein profiling methodologies, including mass spectrometry (MS)-based methods, to examine the DLPFC of SCZ patients. [12] [13] [14] [15] [16] [17] [18] [19] [20] Converging results from these studies have supported the case for synaptic, oxidative stress, mitochondrial and metabolic dysfunction in the disorder. In support of this, the recent application of state-of-the-art metabonomic platforms and informatics tools have identified alterations in markers of energy and neurotransmitter metabolism in sub-regions of the DLPFC of SCZ patients, 17, 21 and in animal models of antipsychotic drug treatment. 22 However, most global profiling studies using post-mortem brain tissue have been performed on subjects who have been treated with varying lifetime antipsychotic medication doses. Although the confounding effects of factors such as post-mortem interval and tissue pH have been investigated in molecular profiling studies, [23] [24] [25] [26] those associated with cumulative lifetime antipsychotic doses have not been addressed fully. This is likely to be an important factor, as neuroimaging analyses of SCZ subjects have demonstrated a correlation between cumulative antipsychotic dose and specific anatomical and cellular alterations. 27, 28 With this in mind, we have attempted to identify the molecular signatures associated with the inherent pathological processes, as well as antipsychotic drug-induced changes in DLPFC tissue from SCZ subjects who had received different cumulative lifetime antipsychotic doses. We conducted a parallel profiling study using label-free liquid chromatography-mass spectrometry (LC-MS E )-based proteomic and proton nuclear magnetic resonance ( 1 H NMR) spectroscopy based metabonomic approaches. We also included DLPFC tissue from bipolar disorder (BPD) subjects in the analysis, to determine the specificity of any observed biomarkers for SCZ given that there is an aetiological overlap between SCZ and BPD and, epidemiological and genetic linkage studies have also identified a number of shared susceptibility loci between these two disorders. 29 
Materials and methods

Tissue samples
A total of 60 post-mortem DLPFC Broadmann Area 9 grey matter samples were obtained from the Stanley Medical Research Institute (Bethesda, MD, USA). The average fluphenazine mg equivalent (FME) was used as an indicator of cumulative lifetime antipsychotic dose. 30 SCZ samples were separated into three demographically-matched groups according to FME: group (1) low-cumulative-medication ((L-SCZ), FME: 6515±6465, n = 10 (including 2 drug-naive with FME = 0 and 2 with FMEp600)), group (2) mediumcumulative-medication ((M-SCZ), FME: 86200 ± 47499, n = 10), and group (3) high-cumulative-medication ((H-SCZ), FME: 182500 ± 123855, n = 10). The medication groups were chosen to optimize the balance of groups such that they had the maximum number of patients and the least overlap in FME dose. The mean FME dose between the medication groups was significantly different (P = 0.0005). In addition, 10 BPD and 10 control (CT) subjects were matched and analysed. An additional batch of 10 CTs was matched specifically to H-SCZ subjects as the latter was not matched to the previous CT group with respect to gender. Unless stated otherwise, samples were matched for post-mortem brain interval, pH, age of onset, age of death, duration of illness and gender (summary of demographic details and statistical values are shown in Tables 1a and b; additional  details are provided in Supplementary Tables S1 and  S2) . Samples from H-SCZ patients and matched CTs were used for Western blot validation analyses only. As the average brain pH of H-SCZ patients was significantly lower than that of the CTs, Pearson correlation analyses were performed using GraphPad PRISM v5 (San Diego, CA, USA) to confirm that there were no effects of pH on protein expression (average of À0.40 and 0.34, P > 0.05). Approximately 70 mg of tissues were sectioned (15 mm slices) using a Leica Cryostat tissue sectioning device (Milton Keynes, UK), collected into pre-chilled lysing matrix D tubes (MP Biomedicals, Cambridge, UK) and stored at À80 1C until use.
Experimental design
Fractionation of post-mortem DLPFC tissue (n = 60) from all subject groups (Tables 1a and b) was performed to increase proteome coverage of membrane-associated proteins. In the first stage of this study, membrane protein fractions from L-SCZ, M-SCZ, BPD and CTs were analysed by LC-MS E . In the next stage, differentially expressed proteins were validated by Western blot analysis using membrane and soluble fractions, and unfractionated total brain lysate samples across all five groups (L-SCZ, M-SCZ, H-SCZ, BPD and CTs). In the final stage, 1 H NMR spectroscopy metabonomic analysis was carried out for L-SCZ, M-SCZ and CTs. The same analysis for BPD samples from this brain collection was conducted previously. 31 Subcellular proteome fractionation and protein purification/digestion Brain tissue sections were processed using the Subcellular Proteome Extraction Kit (Merck; Nottingham, UK) as described previously. [32] [33] [34] Briefly, tissues were homogenized in 1 ml ice cold extraction buffer I containing 5 ml protease inhibitor cocktail at 4 1C using the FastPrep FP120 cell disrupter (Qbiogene; Cambridge, UK) set at speed of 4 for 5 s. Homogenates were incubated on a rotary shaker for 30 min at 4 1C and centrifuged at 11 000 g for 10 min. The supernatants (fraction I, enriched soluble proteins) were collected and pellets were suspended in 1 ml of ice cold extraction buffer II containing 5 ml protease inhibitor by first flicking the tubes and then mixing on a rotary shaker for 60 min at 4 1C. Following centrifugation at 6000 g for 10 min, the supernatants (fraction II, enriched membrane proteins) were collected. Approximately 200 mg of proteins from fraction II were precipitated using the ProteoExtract s Protein Precipitation Kit (Merck), reduced, alkylated and digested using the all-in-one trypsin digestion kit (Merck). Trypsin was obtained from Promega (Madison, WI, USA).
LC-MS
E analysis LC-MS E was carried out and the reproducibility and quantitative reliability was assessed as described previously. 35 To minimise systematic batch effects, sample preparation and MS acquisition were performed in a randomized order. The PLGS2.3 software was used for ion detection and clustering [36] [37] [38] [39] and the embedded ion accounting algorithm employed for searching the Homo Sapiens complete proteome fasta sequence Integr8 database (http://www.ebi.ac. uk/integr8/FtpSearch.do?orgProteomeId = 25; version 25), appended with Saccharomyces cerevisiae enolase sequence (P00924). Data were normalized using the Trackstats software (Waters; Milford, MA, USA) and filtered for replication using R (www.r-project.org) with criteria described previously. 35 To perform quantitation on the protein level, peptide correlation analyses (r > 0.5) were performed for every detected protein. 35, 40 To identify significant alterations in protein expression levels between different experimental groups, 2-tailed Student's t-tests were performed (P < 0.05) and false discovery rates were calculated using the Benjamini and Hochberg correction approach. 41 This approach calculates the proportion of statistically significant differences that are actually false positives. Biological process grouping was carried out using the Human Protein Reference Database (http://www.hprd.org/) and the Database for Annotation, Visualization and Integrated Discovery (http://david.abcc.ncifcrf.gov/).
Western blot analysis
Protein samples (10 mg) were resolved on 4-12% NuPAGE Novex Bis-Tris gels (Invitrogen, Paisley, UK) and transferred electrophoretically onto nitrocellulose membranes. Membranes were washed three times for 5 min in phosphate-buffered saline containing 0.1% Tween-20 followed by incubation for 1 h in Odyssey blocking buffer (LI-COR Biosciences; Cambridge, UK) and then overnight at 4 1C with primary antibodies diluted in the same buffer containing 0.1% Tween-20 (Odyssey blocking buffer containing 0.1% Tween-20 (OBB-T)) (details of the primary antibodies are shown in the legend for Figure 2a and Supplementary Figure S1 ). Membranes were washed five times 20 min in phosphate-buffered saline containing 0.1% Tween-20 followed by incubation with the appropriate infrared dye-linked secondary antibodies (800CW goat anti-mouse, 680CW goat anti-rabbit and 800CW goat anti-rat; LI-COR Biosciences) in OBB-T in the dark. Images were acquired using the Odyssey infrared imaging system (LI-COR Biosciences; Cambridge, UK) and analysed and Abbreviations: BPD, bipolar disorder patients who received mood stabilisers and antidepressants, plus brief antipsychotic treatment (FME not calculated); CT, control or non-psychotic healthy individuals; F, female; FME, Fluphenazine mg equivalents (cumulative lifetime antipsychotic medication dose); H-SCZ, highcumulative-medication schizophrenia patients (FME = 60000-400000); L-SCZ, low-cumulative-medication schizophrenia patients (drug-naive or low cumulative lifetime antipsychotic medication; FME = 0-15000); M, male; M-SCZ, medium-cumulative-medication schizophrenia patients (FME = 34000-180000); NA, not applicable; PMI, post-mortem brain interval; SCZ, schizophrenia. T-test or *Fisher's exact test, significance at P < 0.05.
quantified using the Odyssey v3.0 software (LI-COR Biosciences; Cambridge, UK). Calmodulin was used as internal CT for normalizing protein loading differences as this protein showed no significant differences in abundance between disease and CT by LC-MS E (L-SCZ (P = 0.75), M-SCZ (P = 0.80), BPD (P = 0.28)) and Western blot analysis ( Figure 2b ). For validation purposes, 2-tailed Student's t-tests were conducted and significance was regarded as P < 0.05. Fold changes were calculated by dividing the average integrated intensity readings of disease by CT samples.
H NMR spectroscopy
Separate tissue slices obtained from the same postmortem brain specimens used in the above studies were homogenized while frozen in 1 ml of methanol:-deionised water (1:1) in 2 ml microfuge tubes (Eppendorf; Loughborough, UK) containing a metal bead (Qiagen; West Sussex, UK), using a tissue grinder (Qiagen) set at 30 cycles/second for 5 min. Chloroform (1 ml) was added to produce aqueous and lipid phases. Homogenates were vortexed and centrifuged at 1200 g for B7 min at 5 1C. The upper aqueous phase containing hydrophilic metabolites was collected and left to dry overnight at room temperature to remove methanol before freeze drying. Samples were reconstituted in 700 ml of deuterium oxide and 600 ml was transferred into NMR tubes for analysis. Deuterium oxide provides deuterium field frequency lock for the NMR spectrometer. 1 H NMR spectra were generated at 600.13 MHz on a Bruker DRX-600 spectrometer (Bruker Avance, Bruker GmBH; Rheinstetten, Germany) as described previously. 31 Complete spectra (chemical shift range 0-10 ppm) were processed using the Topspin v2.0 software (Bruker). Spectra were phase and baseline corrected and calibrated using the reference resonances of the CH 3 lactate doublet (1.33 p.p.m.). Any variation effect due to pre-saturation of water was removed by zeroing intensity values between 4.5 and 4.9 p.p.m. To account for concentration differences between samples, data were normalized to the total integrated peak area intensity by converting the integral values into a percentage of the sum of the integral.
Chemometric modelling and interpretation of the 1 H NMR data
To identify metabolites differentiating disease and CT groups, partial least squares discriminant analysis was performed on full resolution 1 H NMR spectral data using SIMCA P v12 (Umetrics AB; Umeå, Sweden). To remove confounding variation, orthogonal-projection to latent structures discriminant analysis was used to model the data using MATLAB v6.5 (The Mathworks Inc, Natick; MA, USA) scripts proprietary to Imperial College, London. This method represents an improvement to the traditional supervised PLS algorithm and enhances the interpretability of spectral variation between classes. 42, 43 To confirm the differences identified by these multivariate analyses, univariate analyses (Wilcoxon-Mann-Whitney U tests 44 ) were performed using GraphPad Prism v5. Significance was regarded as P < 0.05 and fold changes were obtained by calculating the ratio between disease and CT groups.
Results
Quality control
Membrane protein enrichment efficiency in fraction II was demonstrated by Western blot analysis of a DLPFC specimen using subcellular distribution markers. LC-MS E analysis resulted in the identification of 370 proteins in fraction I and 568 proteins in fraction II. Fractionation efficiency, as evaluated by analysis of cellular distribution of these proteins, was demonstrated by identification of a higher proportion of soluble and membrane proteins in fractions I and II, respectively (details are provided in Supplementary Figure S1 ).
MS
Quantitative analysis of fraction II resulted in identification of B30 differentially expressed proteins (P < 0.05) out of the approximate 500 identifiable proteins in L-SCZ and BPD patients, compared with the CT group (Figure 1) . None of the differentially expressed proteins overlapped across the diseases. No significant changes were observed for the M-SCZ patients compared with the same CT group. Differentially expressed proteins were assigned to biological process groups using Human Protein Reference Database and Database for Annotation, Visualization and Integrated Discovery (Table 2 for L-SCZ and  Supplementary Table S3 for BPD). Table 2 also indicates markers which have been reported previously in the literature in association with proteomic or transcriptomic analyses of SCZ DLPFC tissue, thereby providing an additional means of validation as many directions of change reported in the literature agree for our findings.
Western blot validation Confirmation of MS profiling results. Raw P-values for LC-MS E data were corrected for multiple hypothesis testing using the Benjamini-Hochberg false discovery rate method ( Table 2 ). As corrected P-values for differentially expressed proteins were relatively high, Western blot analyses were conducted to confirm changes in L-SCZ and BPD membrane fraction samples. Calmodulin was used as a loading control as this protein was not changed in this study, as determined by LC-MS E and Western blot analyses. Antibodies were selected against seven proteins to represent different functional networks and directional changes in L-SCZ and BPD subjects. These included myelin-associated glycoprotein precursor (MAG), myristoylated alanine-rich C-kinase substrate (MARCKS), neural cell adhesion molecule (NCAM), neuromodulin (GAP43) and NFM. Neuronal nitric oxide synthase (nNOS) was also examined because of its regulatory action on NCAM 45 and functional relevance in SCZ. 46, 47 b-tubulinIII was tested as an example of a protein altered in BPD patients. Western blot analysis validated the expression changes in these proteins, with the exception of MAG (Figures 2a and b) . The predicted change in nNOS was also confirmed in L-SCZ. These results confirmed the reliability of the label-free LC-MS E -based profiling approach. Validation was also conducted using soluble fractions and unfractionated total brain lysates from the L-SCZ patient samples. Overall, most of the changes identified in the membrane fractions were confirmed in the corresponding soluble fractions and total brain lysates (Figure 2b ).
Assessment of disease specificity and effects of lifetime antipsychotic medication in SCZ. LC-MS
E analysis revealed that none of the differentially expressed proteins identified in samples from L-SCZ subjects were found in those from M-SCZ subjects. This was also confirmed by Western blot analyses of membrane fractions from L-SCZ, M-SCZ, H-SCZ and CT samples (Figures 2a and b) . Overall, the results confirmed that the levels of MARCKS, GAP43 and nNOS were changed in L-SCZ, but not in M-SCZ and H-SCZ. This suggested that abnormal expression of these proteins may be a primary disease change and not a medication effect. However, NFM did not show a clear pattern of expression relating to medication. NCAM was increased significantly in all SCZ medication groups and in BPD samples. This suggested that NCAM expression may not be affected by lifetime antipsychotic levels or mood stabilizer treatment and that it is not specific to SCZ. The LC-MS E results showed no overlap in the differentially expressed protein profiles of SCZ and BPD subjects (Table 2 and Supplementary Table S3) , as confirmed by Western blot analysis (Figure 2b ). Biological process grouping using Human Protein Reference Database and Database for Annotation, Visualization and Integrated Discovery also showed no overlap (Figure 1 ). The most notable changes for SCZ were 15 differentially expressed proteins involved in cell communication and 7 metabolism proteins, whereas BPD was marked by alterations of 8 cell communication proteins and 7 cell growth proteins (Figure 1 ).
Correlation analysis
The LC-MS E profiling results showed changes in tissues from L-SCZ subjects, but not in M-SCZ individuals. This suggests that these changes are associated with the primary disease state and, moreover, may be normalized with treatment. For this to be the case, expression changes should not only show a group difference according to treatment level, but also a direct relationship to lifetime antipsychotic dose within the group. In order to further investigate this possibility, FME and Western blot expression values from individual SCZ subjects were tested in correlation analyses. GAP43 (r = À0.77, P = 0.025), MARCKS (r = À0.76, P = 0.029) and nNOS (r = À0.90, P = 0.006) expression levels were significantly negatively correlated with FME, consistent with their identification as differentially expressed proteins in the L-SCZ group and their lack of change after more extensive drug treatment comprising the M-SCZ group (Supplementary Figure S2a ). NCAM (r = 0.64, P = 0.085), on the other hand, was not significantly correlated with FME, consistent with the Western blot finding that this protein was altered in both the L-SCZ and the M-SCZ groups. The effects of lifetime antipsychotic dose were further confirmed by demonstrating a significant correlation between FME dose and levels of significantly altered metabolites (for example, alanine (r = 0.64, P = 0.003) and branched amino acids (r = 48, P = 0.039)). Similar to the case of NCAM, glutamine (Gln) levels (r = À0.15, P = 0.55) were also not significantly correlated with FME dose, as it was altered in both medication groups (Supplementary Figure S2b) . We also considered the possibility that the molecular alterations may be confounded by a shorter duration of illness in patients with low FME. Although this factor was well matched between the L-SCZ and M-SCZ groups (P = 0.27), the mean duration of illness was higher in H-SCZ patients, which were investigated separately. Correlation analyses show that duration of illness did not affect expression of key validated proteins or levels of significantly altered metabolites (Supplementary Figure S3) .
H NMR spectroscopy data analysis
Partial least squares discriminant analysis of 1 H NMR spectroscopy data revealed a separation between the L-SCZ or M-SCZ and CT groups. Orthogonal-projection to latent structures discriminant analysis showed the metabolites that are most influential to these separations (Figure 3a) . Specifically, branched amino acids, alanine, creatine and Gln were altered in L-SCZ patients. Most of the metabolites identified using multivariate analyses were confirmed by univariate statistical analysis (Figure 3b ). Of the four metabolites altered in L-SCZ, three (branched chain amino acids, alanine and creatine) were not changed in M-SCZ and only Gln was changed in both groups. In addition, taurine was altered in M-SCZ, but not in L-SCZ.
Discussion
This is the first study employing label-free LC-MS was found to have an effect on a number of proteins and metabolites in SCZ patients. The specificity of the protein expression changes identified in L-SCZ patients was also demonstrated relative to BPD providing evidence for diverging pathologies between the two disorders.
Disease signatures of SCZ and targets of drug effects
Out of the B500 proteins and 16-20 metabolites identified per dataset, 34 proteins and 4 metabolites were altered in L-SCZ patients and only 1 protein (NCAM) and 2 metabolites (glutamate and taurine) were altered in M-SCZ patients. This suggested that a higher cumulative lifetime antipsychotic dose may exert neuroadaptive effects by normalizing some of the inherent molecular changes in SCZ patients, who were either medication-free or had been subjected to a lower cumulative antipsychotic medication dosage throughout life. Therefore, at least some of the differentially expressed proteins identified in L-SCZ patients may represent 'disease signatures' of SCZ as well as representing targets of antipsychotic drug action. These include effects on proteins associated with synaptogenesis, neuritic dynamics, presynaptic vesicle cycling, amino acid and Gln metabolism, and energy buffering systems. Previously, we have identified molecular changes in proteomic 35 and metabonomic 22 studies of rats treated with antipsychotic medications. Some of these markers are altered in opposite directions to those observed in L-SCZ patients, in the present study, providing further support for our findings. For example, antipsychotics affected components of the rat presynaptic vesicle machinery, neurite outgrowth dynamics and synaptogenesis. Nine proteins and two metabolites found in these antipsychotic-treated rats were shown here to be altered in L-SCZ patients (SYN2, GLUD1, GAPDH, NCAM1, ATP2B4, MAG, GNB1, GAP43, NT, Gln and Cr). Synaptogenic alterations during the premorbid stage of illness (gestation, infancy, childhood and adolescence) have been proposed in the context of the neurodevelopmental hypothesis of SCZ. 48 We identified alterations in key regulators of synaptogenesis [49] [50] [51] and synaptic plasticity in L-SCZ patients including neurofascin1 and tyrosine-protein phosphatase nonreceptor type substrate 1 (SIRPA), which have not been previously implicated in SCZ. We also identified changes in the expression of NCAM, which has been reported to be altered in the brain, 19 ,52,53 serum 54 and cerebrospinal fluid (CSF) [55] [56] [57] of SCZ patients. Therefore, these findings support the case for synaptogenic and synaptic plasticity alterations in SCZ patients. 58 These findings are also supported by animal studies showing that an excess of NCAM at the synapse inhibits synaptogenesis. 59 The observation that NCAM was altered in all conditions examined (L-SCZ, M-SCZ, H-SCZ and BPD patients) suggests that it is not affected by either antipsychotic medication or mood stabilisers and that it is not specific to SCZ. Whether it is a non-specific marker of psychiatric illness or a key biological change underlying brain dysfunction in both disorders requires further studies.
Prominent alterations in components involved in synaptic function have been identified by transcriptomic and proteomic profiling studies of SCZ patients. 16, 17, 19 Many of these findings were confirmed in our study and we also identified novel changes in proteins involved in synaptic vesicle recycling/ endocytosis and exocytosis in the L-SCZ patients, again supporting the case for altered presynaptic vesicle cycling in SCZ. Alterations in proteins involved in the synaptic endocytosis machinery such as clathrin coat assembly protein AP180 (SNAP91), Hsc70 interacting protein (Hip) and reticulon1 (RTN1) have not been reported in SCZ before, although synapsin 2 (SYN2) 60, 61 and another reticulon isoform (RTN4) 13, 62 have been implicated previously. Though increases in syntaxin1A (STX1A) expression have been reported in SCZ, [63] [64] [65] we identified novel alterations in other proteins involved in presynaptic exocytosis in L-SCZ patients, including a group of G i/o proteins (Galphai2, GNB1, GNB4, GNAO1), which are involved in the auto-inhibitory feedback mechanism of exocytosis. 66, 67 To our knowledge, only three recent proteomic studies have reported increase in GNB1 expression in the prefrontal cortex of patients. 14, 68, 69 Significant decreases in neuronal size, number and dendritic spine density of the glutamatergic and GABAergic neurons have been observed in DLPFC [5] [6] [7] [8] and several other brain regions 6, 70, 71 of SCZ patients. We identified alterations in a number of regulators of growth cone path finding, cell shape, structural integrity, spine dynamics and neuronal morphology. Therefore, these findings suggest a link between the aberrant levels of regulators of neuritic dynamics and the macroscopic brain pathology in SCZ. While increased GAP43 expression has been reported in the brain of SCZ patients, 65, 72, 73 this is the first report showing alterations in MARCKS, Ras-related protein Rap-2A (RAP2A) and NF-M at the protein level in the DLPFC of L-SCZ patients. In addition, altered MARCKS expression in SCZ has been reported only at the transcript level 73 and NFM was found to be decreased in one study in a different brain region (anterior temporal lobe) of SCZ patients. 74 Whether these changes are primary or secondary to the disease process remain to be addressed.
Elevated Gln levels have been reported in the DLPFC 75 and other brain regions of drug-naive and medicated SCZ patients. [76] [77] [78] Our findings of increased Gln concentration and glutamate dehydrogenase expression in L-SCZ and/or M-SCZ patients are consistent with these results. Gln, or Gln-derived ammonia in excessive levels has detrimental effects on mitochondrial function as this results in excessive production of free radicals, reactive oxygen species, oxidative stress and increased nNOS expression, [79] [80] [81] as confirmed by Western blot analysis in this study. This suggests a possible link between Gln-induced neurotoxicity and mitochondrial dysfunction in patients 82 and is consistent with the findings from our colleagues 17 who reported mitochondrial dysfunction, energy metabolism defects and increased oxygen and reactive oxygen species metabolism pathways in the DLPFC of SCZ patients.
Creatine has been found to be decreased in the anterior cingulate cortex and parieto-occipital cortices of medicated SCZ patients 83 and increased in the DLPFC (BA46) of medicated patients. 21 We demonstrated that creatine (Cr) was increased in the DLPFC (Broadmann Area 9) of L-SCZ patients and not in M-SCZ patients. Elevations in Cr concentration may be indicative of a regulatory response to increased energy turnover since at times of significant energy demand or crisis (for example, hypoxic damage in SCZ 17 ), phospho-Cr is rapidly dephosphorylated to enable transfer of the phosphoryl group to ADP to form ATP and Cr. 84 Evidence demonstrating overexpression of creatine kinase in patients 69, 85 supports this possibility. Increased Cr levels may also reflect a neuroprotective response mechanism to mitochondrial damage and neurotoxicity, 86 as it also acts as a direct anti-oxidant by scavenging reactive oxygen species. Cr also regulates glycolysis, prevents reduced energy stores and improves neuronal function. 87 By identifying for the first time, that both Ala and branched amino acids were significantly decreased, we hypothesize that the uptake process and metabolism of these amino acids may be altered in SCZ, although future work must be conducted to confirm these findings. Reductions in these amino acids may have implications in the ammonia transport system, 88 neurotransmitter synthesis 89, 90 and energy metabolism 90 given their indispensable roles in these processes.
Specificity of the changes in L-SCZ patients relative to BPD We identified a different panel of differentially expressed membrane associated proteins in L-SCZ and BPD patients. In contrast to SCZ, BPD showed changes in a group of axon growth/branch promoting signal transduction proteins and structural proteins. These findings suggest abnormal signalling cascades regulating axon branching and cytoskeleton reorganization in BPD. This is consistent with previous studies, which identified disruptions of second messenger cascades involving CAMKs and ERK/ MAPK, 91 abnormal G protein function and expression in brain and peripheral tissues of BPD patients. 92 Increased b-tubulin expression has been found in a recent proteomic profiling study 16 and reductions in glial fibrillary acidic protein have also been reported in various brain regions of BPD patients. 93, 94 These data demonstrate specificity of the detected changes in SCZ and BPD and suggest diverging pathological processes between the two disorders. However, as the BPD subjects were treated with mood stabilisers, effects of these drugs cannot be ruled out.
Methodological issues
The quantitative reliability of the label-free LC-MS E proteomic profiling approach for robust identification of expression differences was demonstrated by Western blot validation of soluble and membrane fractions, as well as total brain lysates. As the corrected P-values were relatively high for the SCZ and BPD datasets (ranging from 0.25 to 0.58), we propose a more relaxed corrected P-value cutoff threshold for brain studies using this label-free proteomic profiling platform. A microarray study conducted by Kaiser et al. 95 supports this view by demonstrating that the rate of confirmation of results by real-time quantitative polymerase chain reaction (RT-QPCR) was 100% for genes with a corrected P-value < 0.1 and 82% for genes with a corrected P-value < 0.5. Although careful matching of the brain tissue samples can increase confidence of the results obtained, the realistic fact is that there are a number of additional confounders, which cannot be controlled for and remain inherent caveats to these studies. These include factors such as heterogeneity and phenotypic diversity of brain tissue, possible changes in small subpopulations of brain cells, and subtle differences in the cellular distribution of proteins across different brain and cellular compartments. The presence of different SCZ disease subtypes may also represent a source of heterogeneity. Therefore, we propose validation of results using an independent brain series although obtaining further well-characterized post-mortem samples from L-SCZ patients remains difficult. Although we have made some progress toward distinguishing the effects of antipsychotic medication and SCZ disease signatures, there are several limitations associated with the present study. Patients were medicated differently up to the time of death and for different periods of time. In addition, as patients were treated by a mixture of typical and atypical antipsychotic drugs, the differential effects of these drugs cannot be addressed in the present study. Though we have previously addressed this effect in rat animal models, 96 future studies are warranted to investigate this effect in patients. Although the effects of medication were demonstrated by comparing L-SCZ and M-SCZ patients, further confirmation of these effects by direct statistical comparison of L-SCZ and H-SCZ (matched to their own CTs) patients was not possible because of their differences in the mean duration of illness. Duration of illness is an important confounding factor, 97 which challenges post-mortem studies investigating drug naive or low-cumulative-medication patient cohorts, as these patients often have short durations of illness up to the time of death or may be in an earlier disease stage compared with chronically ill patients, which live longer to receive treatments. Furthermore, patient records assume compliance in taking the prescribed medication, and compliance is known to be poor in the case of SCZ. 98 The FME is a proxy measure of drug exposure based on historical records and does not take these factors into account. Moreover, as antipsychotic medication is the mainstay of treatment for SCZ, patients who have never received medication may have additional variation distinct from those seen in medicated patients such as higher social functioning. A limitation associated with the BPD patients was that cumulative drug dosage (antidepressants and mood stabilisers or antipsychotic drug) information for these patients is not available, and thus may represent another confounding factor.
Conclusion
The present study demonstrates the utility of subproteome and metabonome profiling approaches for providing new insights into the pathophysiology and therapeutic mechanisms in SCZ. We found that the cumulative lifetime antipsychotic medication exerts a considerable effect on a number of proteins and metabolites in the DLPFC of patients. This suggests careful interpretation of data available to account for the confounding effects of lifetime medication levels. We identified novel protein and metabolite disease signatures of SCZ and targets of antipsychotic drug effects involved in synaptic connexion, neuritic dynamics, presynaptic vesicle cycling, amino acid metabolism and energy buffering systems. Finally, with the exception of NCAM, we found no changes in common between SCZ and BPD, indicating the specificity of the changes and distinct pathologies. Altogether, our results may impact development of new drug discovery strategies. Furthermore, knowledge that most of the biomarkers identified are released into a variety of body fluids and peripheral tissues may facilitate translation of these markers to blood-based assays.
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